Association of "J-shaped" curves and coronary revascularization status: A substudy of the International Verapamil SR-Trandolapril study (INVEST)

被引：0
|
作者：
Denardo, Scott J. [1 ]
Messerli, Franz H. [2 ]
Gaxiola, Efrain [3 ]
Cooper-DeHoff, Rhonda M. [1 ]
Handberg, Eileen M. [1 ]
Champion, Annette [4 ]
Pepine, Carl J. [1 ]
Zhou, Qian [4 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] St Lukes Roosevelt Hosp, New York, NY USA
[3] Inst Cardiovasc Guadalajara, Guadalajara, Jalisco, Mexico
[4] Abbott Labs, Abbott Pk, IL USA
来源：
CIRCULATION | 2007年 / 116卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：842 / 842
页数：1
相关论文
共 50 条
  • [21] Impact of heart rate on outcomes in hypertensive CAD patients, findings from the international verapamil SR-trandolapril study (INVEST)
    Kolloch, R.
    Champion, A.
    Zhou, Q.
    Mancia, G.
    Pepine, C.
    EUROPEAN HEART JOURNAL, 2005, 26 : 671 - 672
  • [22] MADD variants and risk of cardiovascular events in the international verapamil SR/trandolapril study -: Genetic substudy (invest genes).
    Price, E. T.
    Pacanowski, N.
    Cooper-DeHoff, R. M.
    Pepine, C. J.
    Johnson, J. A.
    Zineh, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S82 - S83
  • [23] Verapamil- and atenolol-based strategies are equally effective in black patients with hypertension and coronary artery disease: A subanalysis of the international verapamil SR-trandolapril study (INVEST)
    Jamerson, K
    Champion, A
    Zhou, Q
    Pepine, C
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 109A - 109A
  • [24] Genetic Variation in the β2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)
    Niu, Yuxin
    Gong, Yan
    Langaee, Taimour Y.
    Davis, Heather M.
    Elewa, Hazem
    Beitelshees, Amber L.
    Moss, James I.
    Cooper-DeHoff, Rhonda M.
    Pepine, Carl J.
    Johnson, Julie A.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2010, 3 (06) : 548 - 555
  • [25] Stroke outcome in hypertensive CAD patients treated with verapamil SR-(VE) and atenolol-(At) based strategies: The international verapamil SR-trandolapril study (INVEST)
    Coca, A
    Benetos, A
    Hewkin, A
    Champion, A
    Pepine, C
    JOURNAL OF HYPERTENSION, 2004, 22 : S114 - S114
  • [26] Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-trandolapril STudy [INVEST])
    Cooper-DeHoff, Rhonda
    Cohen, Jerome D.
    Bakris, George L.
    Messerli, Franz H.
    Erdine, Serap
    Hewkin, Ann C.
    Kupfer, Stuart
    Pepine, Carl J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (07): : 890 - 894
  • [27] Risk of adverse cardiovascular outcomes and new diabetes with combination therapy in hypertensive patients with coronary artery disease: the INternational VErapamil SR-Trandolapril STudy (INVEST)
    Mancia, G
    Keltai, M
    Erdine, S
    Hewkin, A
    Kupfer, S
    Pelpine, CJ
    EUROPEAN HEART JOURNAL, 2004, 25 : 423 - 424
  • [28] Beta adrenergic receptors polymorphisms are associated with response to beta-blocker therapy in the international verapamil SR-trandolapril study (invest).
    Gong, Y
    Beitelshees, AL
    Stauffer, LA
    Langaee, TY
    Cooper-DeHoff, RM
    Pepine, CJ
    Johnson, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P30 - P30
  • [29] Cacnaic polymorphisms and cardiovascular outcomes in the international verapamil SR/trandolapril study-genetic substudy (invest-genes).
    Navare, H. A.
    Beitelshees, A. L.
    Gong, Y.
    Langaee, T. Y.
    Cooper-Dehoff, R. M.
    Pepine, C. J.
    Johnson, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S4 - S4
  • [30] A GWAS OF RESISTANT HYPERTENSION IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST) AND SECONDARY PREVENTION OF SUBCORTICAL STROKES (SPS3).
    El Rouby, N.
    McDonough, C. W.
    Gong, Y.
    Mcclure, L. A.
    Mitchell, B. D.
    Horenstein, R. B.
    Talbert, R. L.
    Bradford, Y.
    Crawford, D. C.
    Ritchie, M. D.
    Gitzendanner, M. A.
    Takahashi, A.
    Tanaka, T.
    Kubo, M.
    Pepine, C. J.
    Benavente, O. R.
    DeHoff, R. M.
    Johnson, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S27 - S28
12345